Home > Journals > Minerva Anestesiologica > Past Issues > Articles online first > Minerva Anestesiologica 2020 Nov 11

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Anestesiologica 2020 Nov 11

DOI: 10.23736/S0375-9393.20.14859-4

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Contextualizing cardiac dysfunction in critically ill patients with COVID-19

Guido TAVAZZI 1, 2, Francesco CORRADI 3, 4 , Francesco MOJOLI 1, 2, Francesco FORFORI 3, Gabriele VIA 5

1 Unit of Anaesthesia and Intensive Care, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; 2 Anesthesia and Intensive Care, Fondazione Policlinico San Matteo Hospital IRCCS, Pavia, Italy; 3 Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy; 4 Anaesthesia and Intensive Care Unit, E.O. Ospedali Galliera, Genoa, Italy; 5 Cardiac Anesthesia and Intensive Care Department, Fondazione Cardiocentro Ticino, Lugano, Switzerland


PDF


Acute cardiac injury incidence in COVID-19 is about 13 times higher in the ICU/severely ill than in less critical patients. Patients with cardiovascular comorbidities seem to be more prone to develop higher acuity of the infection, and myocardial injury has been reported amongst them in up to 15% of those hospitalized and up to 30% of ICU-admitted ones. The symptoms of over ischemia/heart failure may be challenging to distinguish as dyspnoea and chest discomfort overlap with those due to COVID-19. Therefore, beside close monitoring with ECG, biomarkes and, in case of demonstrated cardiac involvement, echocardiography, strategies to improve myocardial oxygen delivery should be promptly applied. The cytokine release with complement and iNO dysregulation are established mechanisms potentially leading to sepsis-related cardiomyopathy, making sepsis per se one of the potential mechanism leading to acute cardiac injury in COVID-19 patients. Moreover, the hyper-inflammation with endothelial dysfunction is likely be responsible of both pulmonary in-situ platelet aggregation and deep thrombosis potentially leading to severe pulmonary embolism and right ventricular failure. Besides the customary antithrombotic prophylaxis for critical patients, D-dimer levels and tighter coagulation monitoring are recommended and should guide the choice for anticoagulation treatment. We summarize the current knowledge regarding cardiovascular involvement in patient with COVID-19.


KEY WORDS: SARS-Cov2; ACE 2 receptor; Right ventricular dysfunction; Acute myocardial injury

top of page